[{"address1": "1800 Owens Street", "address2": "Suite 900", "city": "San Francisco", "state": "CA", "zip": "94158", "country": "United States", "phone": "415 906 4324", "website": "https://www.vir.bio", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.", "fullTimeEmployees": 408, "companyOfficers": [{"maxAge": 1, "name": "Dr. Marianne  De Backer M.B.A., M.Sc., Ph.D.", "age": 55, "title": "CEO & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 4467539, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jennifer Eileen Towne Ph.D.", "title": "Executive VP & Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Vanina  de Verneuil J.D.", "title": "Executive VP, General Counsel & Corporate Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Arran  Attridge", "title": "Senior Vice President of Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Toby  Medaris", "title": "Senior Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Antonio  Lanzavecchia M.D., Ph.D.", "title": "SVP & Senior Research Fellow", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Amalio  Telenti M.D., Ph.D.", "title": "Executive VP & Senior Research Fellow", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark D. Eisner M.D., M.P.H.", "age": 58, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mika Kakefuda Derynck M.D.", "age": 61, "title": "Executive Vice President of Therapeutic Head Oncology", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1740787200, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 8.07, "open": 8.01, "dayLow": 7.935, "dayHigh": 8.22, "regularMarketPreviousClose": 8.07, "regularMarketOpen": 8.01, "regularMarketDayLow": 7.94, "regularMarketDayHigh": 8.22, "payoutRatio": 0.0, "beta": 1.166, "forwardPE": -2.1283422, "volume": 838720, "regularMarketVolume": 838720, "averageVolume": 2046825, "averageVolume10days": 1292530, "averageDailyVolume10Day": 1292530, "bid": 5.89, "ask": 10.17, "bidSize": 2, "askSize": 2, "marketCap": 1091658368, "fiftyTwoWeekLow": 6.56, "fiftyTwoWeekHigh": 14.45, "priceToSalesTrailing12Months": 14.711386, "fiftyDayAverage": 9.3124, "twoHundredDayAverage": 8.846875, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 284203552, "profitMargins": 0.0, "floatShares": 92108174, "sharesOutstanding": 137143008, "sharesShort": 7670907, "sharesShortPriorMonth": 7855176, "sharesShortPreviousMonthDate": 1736899200, "dateShortInterest": 1739491200, "sharesPercentSharesOut": 0.055999998, "heldPercentInsiders": 0.119969994, "heldPercentInstitutions": 0.76551, "shortRatio": 5.4, "shortPercentOfFloat": 0.0912, "impliedSharesOutstanding": 137143008, "bookValue": 8.399, "priceToBook": 0.94773185, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -521960000, "trailingEps": -3.83, "forwardEps": -3.74, "enterpriseToRevenue": 3.83, "enterpriseToEbitda": -0.558, "52WeekChange": -0.29210526, "SandP52WeekChange": 0.121255875, "quoteType": "EQUITY", "currentPrice": 7.96, "targetHighPrice": 110.0, "targetLowPrice": 14.0, "targetMeanPrice": 32.0, "targetMedianPrice": 20.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 905347968, "totalCashPerShare": 6.601, "ebitda": -508912000, "totalDebt": 97891000, "quickRatio": 7.608, "currentRatio": 8.712, "totalRevenue": 74205000, "debtToEquity": 8.509, "revenuePerShare": 0.545, "returnOnAssets": -0.19722, "returnOnEquity": -0.38091, "grossProfits": -404440000, "freeCashflow": -363377376, "operatingCashflow": -446352000, "revenueGrowth": -0.263, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -8.33328, "financialCurrency": "USD", "symbol": "VIR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Vir Biotechnology, Inc.", "longName": "Vir Biotechnology, Inc.", "postMarketTime": 1741393138, "regularMarketTime": 1741381201, "exchange": "NMS", "messageBoardId": "finmb_419881198", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -1.3630689, "regularMarketPrice": 7.96, "marketState": "CLOSED", "epsTrailingTwelveMonths": -3.83, "epsForward": -3.74, "epsCurrentYear": -3.37048, "priceEpsCurrentYear": -2.3616815, "fiftyDayAverageChange": -1.3523998, "fiftyDayAverageChangePercent": -0.1452257, "twoHundredDayAverageChange": -0.88687515, "twoHundredDayAverageChangePercent": -0.10024728, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.0 - Buy", "cryptoTradeable": false, "corporateActions": [], "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1570800600000, "postMarketChangePercent": -1.00502, "postMarketPrice": 7.88, "postMarketChange": -0.0799999, "regularMarketChange": -0.10999966, "regularMarketDayRange": "7.94 - 8.22", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 2046825, "fiftyTwoWeekLowChange": 1.4000001, "fiftyTwoWeekLowChangePercent": 0.21341465, "fiftyTwoWeekRange": "6.56 - 14.45", "fiftyTwoWeekHighChange": -6.49, "fiftyTwoWeekHighChangePercent": -0.44913495, "fiftyTwoWeekChangePercent": -29.210526, "earningsTimestamp": 1740603900, "earningsTimestampStart": 1746010740, "earningsTimestampEnd": 1746446400, "earningsCallTimestampStart": 1740605400, "earningsCallTimestampEnd": 1740605400, "isEarningsDateEstimate": true, "displayName": "Vir Biotechnology", "trailingPegRatio": null, "__fetch_time": "2025-03-08"}]